Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1] : vimarsana.com

$
Free Cash Flow
$2,300 - $2,700
___________

Includes the full year expected performance for the planned divestitures and excludes any potential related costs, such as taxes and transaction costs,...

Related Keywords

China , Shanghai , India , United States , Hyderabad , Andhra Pradesh , Scotta Smith , Biocon Biologics , Sanjeev Narula , Rajiv Malik , Viatris Inc , Pfizer Inc , Famy Life Sciences , Instagram , Oyster Point Pharma Inc , Biocon Biologics Limited , Company Annual Report On Form , Prnewswire Viatris Inc , Linkedin , Mapi Pharma Ltd , Twitter , Morris , Nasdaq , Youtube , Reports Total Revenues , Cash Provided , Operating Activities , Free Cash Flow , Results Signal Expected Beginning , Full Year Total Revenues , Free Cash Flow Expected , Debt Year , Announce Planned Divestitures , Directors Declares Quarterly Dividend , President Rajiv Malik , Key Terms , Emerging Markets , Total Revenues , Financial Condition , Viatri Quarterly Report , Global Healthcare Gateway , Private Securities Litigation Reform Act , Annual Report , Fair Disclosure , Viatri Phase , Consolidated Statements , Product Net Sales , Key Segment Products , Adjusted Net , Months Ended , Reverse Morris Trust , Oyster Point Pharma , Upjohn Distributor Markets , Mapi Pharma , Famy Life Sciences Private Limited , Developed Markets , Income Statement Line , Revenue Code , Free Cash , Markets ,